A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Multi-Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TDM-105795 in Healthy Male Subjects With Androgenetic Alopecia (AGA)
In the register
The register attaches this trial to TDM-105795 (TechnoDerma Medicines), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 1
- Sponsor
- Technoderma Medicines Inc.
- Participants (registry)
- 32
- Start
- February 2022
- Primary completion
- November 2022
- Study completion
- February 2023
- Last registry update
- March 2023
- Countries
- United States
Conditions studied: Alopecia, Androgenetic
Interventions: TDM-105795, Placebo
Other trials of TDM-105795
Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia
A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects
A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.